downgrad under-perform po
limit visibl expect stock pressur remain
downgrad neutral under-perform reduc price
object po ep current deal
number busi headwind drive pressur core script growth also
suffer slower front-of-stor growth due strateg pivot toward
privat label/high gross margin product ep perform well core
profit growth busi remain challeng see challeng
rebound intermedi basi addit newly-introduc amazon threat
even doesnt immedi financi impact creat long-term
competit question well uncertainti around multipl see clariti
around better long-term profit growth pathway look revisit particularli
driven transform interim see particularli
pressur work partnership plan expect
stock remain range-bound even today intra-day stock move thu move
under-perform rate
increas ep reduc
increas ep driven lower tax rate
sg manag quarter howev reduc ep
ep respect reflect on-going margin
headwind new po repres ep discount histor
rang reflect recent ebit growth challeng well emerg
competit threat amazon follow pillpack acquisit
upcom event catalyst
possibl catalyst includ sale data iqvia releas tomorrow june
key driver improv narr go forward long-term plan
augment profit growth model allud number partnership
pursu effort creat relev within healthcar recent
announc pilot partnership link includ build-out
two in-stor clinic kc
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
walgreen follow complet rite
aid store acquisit largest global
pharmaci nearli store us
alon compani also oper intern
pharmaci busi primarili compos
boot pharmaci unit kingdom
allianc healthcar intern wholesal
distributor pharmaceut medic
product europ walgreen headquart
under-perform rate predic
market headwind competit dynam
exacerb concern around pend
amazon entri market core profit
dollar growth slow think limit visibl
creat challeng near-term stock
perform view range-bound
note earn call
note prepar remark
new partnership kc
first time complement nurs practition
opportun decid expand
partnership outsid kc
sinc establish market share grown
price conveni retail need competit
part due compani move market
partli due chang consum expect
partnership lh progress well look forward expand
readi expand pilot program beyond gainesvil fl
partnership progress well roll
across acquir store
integr new store progress well
experienc addit cost due transit cost expect
sig earn contribut fy
exclud prime contribut pharmaci busi grow mid-singl
digit led specialti brand inflat off-set reimburs pressur
on-going reimburs pressur higher proport specialti
impact pharmaci gm
compani feel posit part sell season
expect see increas y/i contribut acquir store
market share increas y/i
posit impact strateg pharmaci partnership off-set part
retail sale weaker cold flu season last quarter
adjust ebit cc due higher adj earn exclud
gener procur margin cost inflationari pressur off-set
posit impact higher sale
share repurchas program expiri date would expect
complet next three year without larg
sell minor interest premis expect deal close
expect book after-tax gain
expect relationship continu premis exclus
note
manag appear particularli worri confid
compet focu build commun hub
awar chang environ want deal due
pressure/emot
share repurchas program limit larg right
continu develop specialti strategi
two model includ central specialti commun model close
patient live clinic
relationship global manufactur
strong wholesal relationship uk
challeng year usual
continu well prime continu grow optum
issu aet move non-pref
relationship
see need chang relationship current
support price chang transpar custom
believ transpar system overal
price object base ep
multipl five-year averag absolut basi around discount
five-year averag reflect view walgreen core retail pharmaci busi
long-term structur pressur must diversifi stabl busi line
improv growth outlook
upsid risk better expect gener save addit volum
econdisc/rit aid new partnership healthcar support long-term growth
faster expect growth prime relationship downsid risk
po greater expect prescript attrit part relationship
integr risk risk amazon anoth disrupt forc
enter suppli chain market lack avail attract capit deploy
michael cherni herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
